118 related articles for article (PubMed ID: 29800519)
1. Telomerase Responsive Delivery of Doxorubicin from Mesoporous Silica Nanoparticles in Multiple Malignancies: Therapeutic Efficacies against Experimental Aggressive Murine Lymphoma.
Srivastava P; Hira SK; Sharma A; Kashif M; Srivastava P; Srivastava DN; Singh RA; Manna PP
Bioconjug Chem; 2018 Jun; 29(6):2107-2119. PubMed ID: 29800519
[TBL] [Abstract][Full Text] [Related]
2. Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles.
Srivastava P; Hira SK; Paladhi A; Singh R; Gupta U; Srivastava DN; Singh RA; Manna PP
J Mater Chem B; 2020 Feb; 8(7):1411-1421. PubMed ID: 31974541
[TBL] [Abstract][Full Text] [Related]
3. Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton's lymphoma tumour.
Reddy LH; Sharma RK; Murthy RS
J Drug Target; 2004; 12(7):443-51. PubMed ID: 15621669
[TBL] [Abstract][Full Text] [Related]
4. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
5. Bioresponsive mesoporous silica nanoparticles for triggered drug release.
Singh N; Karambelkar A; Gu L; Lin K; Miller JS; Chen CS; Sailor MJ; Bhatia SN
J Am Chem Soc; 2011 Dec; 133(49):19582-5. PubMed ID: 21981330
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-dCas9-Guided and Telomerase-Responsive Nanosystem for Precise Anti-Cancer Drug Delivery.
Ma Y; Mao G; Wu G; Cui Z; Zhang XE; Huang W
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7890-7896. PubMed ID: 33513005
[TBL] [Abstract][Full Text] [Related]
7. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
[TBL] [Abstract][Full Text] [Related]
8. Telomerase triggered drug release using a SERS traceable nanocarrier.
Zong S; Wang Z; Chen H; Zhu D; Chen P; Cui Y
IEEE Trans Nanobioscience; 2014 Mar; 13(1):55-60. PubMed ID: 24594515
[TBL] [Abstract][Full Text] [Related]
9. Glutathione- and light-controlled generation of singlet oxygen for triggering drug release in mesoporous silica nanoparticles.
Wong RCH; Ng DKP; Fong WP; Lo PC
J Mater Chem B; 2020 May; 8(20):4460-4468. PubMed ID: 32369087
[TBL] [Abstract][Full Text] [Related]
10. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
11. Gold nanoparticle-gated mesoporous silica as redox-triggered drug delivery for chemo-photothermal synergistic therapy.
Yang Y; Lin Y; Di D; Zhang X; Wang D; Zhao Q; Wang S
J Colloid Interface Sci; 2017 Dec; 508():323-331. PubMed ID: 28843922
[TBL] [Abstract][Full Text] [Related]
12. ATP-Decorated Mesoporous Silica for Biomineralization of Calcium Carbonate and P2 Purinergic Receptor-Mediated Antitumor Activity against Aggressive Lymphoma.
Srivastava P; Hira SK; Srivastava DN; Singh VK; Gupta U; Singh R; Singh RA; Manna PP
ACS Appl Mater Interfaces; 2018 Feb; 10(8):6917-6929. PubMed ID: 29392934
[TBL] [Abstract][Full Text] [Related]
13. A Telomerase-Specific Doxorubicin-Releasing Molecular Beacon for Cancer Theranostics.
Ma Y; Wang Z; Zhang M; Han Z; Chen D; Zhu Q; Gao W; Qian Z; Gu Y
Angew Chem Int Ed Engl; 2016 Mar; 55(10):3304-8. PubMed ID: 26848056
[TBL] [Abstract][Full Text] [Related]
14. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA.
Han L; Tang C; Yin C
Biomaterials; 2015 Aug; 60():42-52. PubMed ID: 25982552
[TBL] [Abstract][Full Text] [Related]
16. Application of a Y-type-DNA-functionalized nanogold probe featuring specific telomerase recognition and doxorubicin release in cancer cells.
Zhang S; Liang K; Li P; Liu J; Tang B
Analyst; 2020 Mar; 145(6):2152-2158. PubMed ID: 32125312
[TBL] [Abstract][Full Text] [Related]
17. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
18. Hybrid Mesoporous Silica-Based Drug Carrier Nanostructures with Improved Degradability by Hydroxyapatite.
Hao X; Hu X; Zhang C; Chen S; Li Z; Yang X; Liu H; Jia G; Liu D; Ge K; Liang XJ; Zhang J
ACS Nano; 2015 Oct; 9(10):9614-25. PubMed ID: 26316321
[TBL] [Abstract][Full Text] [Related]
19. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional envelope-type mesoporous silica nanoparticles for pH-responsive drug delivery and magnetic resonance imaging.
Chen Y; Ai K; Liu J; Sun G; Yin Q; Lu L
Biomaterials; 2015 Aug; 60():111-20. PubMed ID: 25988726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
